ScinoPharm Taiwan, Ltd. Announces Executive Changes, Effective August 20, 2018
August 01, 2018 at 06:46 pm IST
Share
ScinoPharm Taiwan, Ltd. announced that Chih-Hui Lin, Senior Director of Accounting and Acting Spokesperson and Financial & Accounting Officer and Acting Spokesperson of the company has been replaced by Chih-Ching Hsu, Senior Director of Finance, Head of Corporate Approval, Wholesale and Market Risk Management, HSBC as Financial Officer, effective August 20, 2018.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
